The treatment landscape of multiple myeloma (MM) patients has substantially changed in the last decade thanks to the incorporation of several new drugs and combinations, including second-generation proteasome inhibitors (PI) (carfilzomib, ixazomib), second-generation immunomodulatory drugs (IMIDs) (pomalidomide), and anti-CD38 monoclonal antibodies (MoAb) (daratumumab). This evidence concerns the gene CD38 and plasma cell myeloma.